{"title":"采用 TS-1 和顺铂联合化疗治疗泌尿系统腺癌：回顾性病例系列研究","authors":"Akifumi Omiya , Satoshi Nitta , Shuya Kandori , Reo Takahashi , Ichiro Chihara , Masanobu Shiga , Kosuke Kojo , Yoshiyuki Nagumo , Atsushi Ikeda , Takashi Kawahara , Akio Hoshi , Bryan J. Mathis , Hiromitsu Negoro , Hiroyuki Nishiyama","doi":"10.1016/j.clgc.2024.102149","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>Urinary adenocarcinoma is a rare histological subtype in urinary tract cancers and standard chemotherapy regimens remain unestablished. We retrospectively analyzed the clinical information of patients with rare urinary adenocarcinoma who received TS-1 plus cisplatin chemotherapy at the University of Tsukuba Hospital. In this study, a total of 9 patients were included and 1 and 3 had complete or partial responses, resulting in an overall response rate of 44%. The median follow-up period was 21.2 months (range, 8.5-91.6). The median OS and PFS were 16.2 months (range, 3.6-90.2) and 4.8 months (range, 1.7-20.0), respectively. The major adverse events over Grade 3 were neutropenia in 2 patients (22%) and anemia in 1 patient (11%). This study suggests the efficacy and safety of TS-1 in combination with cisplatin with regard to rare urinary adenocarcinoma. Multicenter, large, and prospective studies are necessary to validate these findings.</p></span></li></ul></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series\",\"authors\":\"Akifumi Omiya , Satoshi Nitta , Shuya Kandori , Reo Takahashi , Ichiro Chihara , Masanobu Shiga , Kosuke Kojo , Yoshiyuki Nagumo , Atsushi Ikeda , Takashi Kawahara , Akio Hoshi , Bryan J. Mathis , Hiromitsu Negoro , Hiroyuki Nishiyama\",\"doi\":\"10.1016/j.clgc.2024.102149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p></p><ul><li><span>•</span><span><p>Urinary adenocarcinoma is a rare histological subtype in urinary tract cancers and standard chemotherapy regimens remain unestablished. We retrospectively analyzed the clinical information of patients with rare urinary adenocarcinoma who received TS-1 plus cisplatin chemotherapy at the University of Tsukuba Hospital. In this study, a total of 9 patients were included and 1 and 3 had complete or partial responses, resulting in an overall response rate of 44%. The median follow-up period was 21.2 months (range, 8.5-91.6). The median OS and PFS were 16.2 months (range, 3.6-90.2) and 4.8 months (range, 1.7-20.0), respectively. The major adverse events over Grade 3 were neutropenia in 2 patients (22%) and anemia in 1 patient (11%). This study suggests the efficacy and safety of TS-1 in combination with cisplatin with regard to rare urinary adenocarcinoma. Multicenter, large, and prospective studies are necessary to validate these findings.</p></span></li></ul></div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1558767324001204\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series
•
Urinary adenocarcinoma is a rare histological subtype in urinary tract cancers and standard chemotherapy regimens remain unestablished. We retrospectively analyzed the clinical information of patients with rare urinary adenocarcinoma who received TS-1 plus cisplatin chemotherapy at the University of Tsukuba Hospital. In this study, a total of 9 patients were included and 1 and 3 had complete or partial responses, resulting in an overall response rate of 44%. The median follow-up period was 21.2 months (range, 8.5-91.6). The median OS and PFS were 16.2 months (range, 3.6-90.2) and 4.8 months (range, 1.7-20.0), respectively. The major adverse events over Grade 3 were neutropenia in 2 patients (22%) and anemia in 1 patient (11%). This study suggests the efficacy and safety of TS-1 in combination with cisplatin with regard to rare urinary adenocarcinoma. Multicenter, large, and prospective studies are necessary to validate these findings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
